michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. I would just kind of look at the history here and ask yourself, are we generally conservative, are we generally aggressive on our projections, right? So you can draw that conclusion, right? And with the comments I made earlier, I mean we wouldn't say a minimum of 15% to 20% growth and 100 basis points to 200 basis points unless like I said, obviously, history would tell you here is look at the last -- I don't know X number of years that we're relatively conservative in how we guide.
And we generally outperformed our expectations, especially the ones we give at the beginning of the year. The question here is will there be a big economic change? Like, nobody knows that. Like, will there be a recession, will there something else happen? Nobody knows that. But if not, we feel more optimistic than pessimistic about things right now. But we tend to under promise and over deliver, so.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. So I -- look, I've been in bioprocessing for over 20 years. And it's an industry and a market that has consistently delivered I would say, prior to COVID, somewhere between 8% and 15% growth on an annual basis. I don't expect that, that will change, right? I think we're going to -- as we all worked through COVID, whether COVID is two years, three years, four years, whatever it is, we're still going to see core growth in the non-COVID part of the marketplace.
And you can see from all the players over the last week or so, they're all citing really great non-COVID base business growth. I still expect for Repligen 15% to 20% type growth for the non-COVID part of our portfolio. And in some years, that's 25%, 30%. Other years, it's going to be at the low end of that range. But we definitely believe that bioprocessing is a healthy, healthy market for us to be in. And we don't see anything to suggest that, that market will slow down in a post-COVID world for the non-COVID part of the market.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. It's hard to predict exactly when we get back to pre-COVID levels, but I think it's pretty astonishing that we've gotten back just here in four months 40% of our peak last year. In just one month, we've made it back. So it's a great trajectory. Let's just keep working on that to keep it going in that direction. When and if we get to the point where we're back to pre COVID, I don't think it will be this year, but definitely, we're headed in the right direction, which is promising.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, I would say we aren't seeing significant self-op conversions in multiple business segments, both in facilities and B&I and higher ed. There are -- we're seeing that and we've got some -- we are working on some opportunities today that are very non-traditional in nature and which I really can't disclose because of the strategic value of that -- those opportunities. So I would say, yes, we do see an increasing trend toward outsourcing, we do see that evidenced in both of our wins so far this year. Corning, for example, one of the last, really big self-op B&I opportunity, that was a great win for the B&I team and again on the facilities side. So, yes, as the short answer, we are seeing more self-op conversion and we expect it to continue.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I think we're very confident in kidney disease that the 30 mg dose that worked in ADVOCATE should really be very similar in the lupus population and obviously, with C3G, we have additional confidence in that. Every patient population is a little bit difference in their PK profiles, but from what we can tell for lupus, I think we're pretty optimistic that it's going to look a lot like the ANCA vasculitis population in terms of the drug confidence.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
They are separate numbers.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
There's a lot in what you've asked. I would say that we're expecting that eCommerce is a little softer in Q2 relative to the 100%-plus comp we generated in Q2 of last year. Probably not reasonable to assume that we would continue at that torrid pace from a year ago. I think the store comps is probably not meaningful compared to last year because of the closures. I would say we're still running down traffic to 2019. That's how we're trying to kind of benchmark ourselves. We've been running ahead of the industry benchmarks that we look at. So the whole industry continues to be down from a store traffic point of view. We've been running better than those results. And our forecasts indicate that, that will get better over time, but that continues to be, I think, kind of one of the key risk that we're monitoring, how quickly will folks feel comfortable getting out and about and being comfortable being back in stores again.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. So thank you, Rommel. So the -- what's interesting about the brands is this is the first time we've kind of leaned out and talked about the powerhouse stable of brands we have. So we've got 10 brands that are $100 million in annual sales, which really speaks to the power and the leverage that you can have in markets regardless of trends and conditions. As it relates to ammo, we've got multiple brands, and you've mentioned Federal and Remington. And they've always had a core set of very loyal followers. So Remington is over a 200-year-old brand, Federal is a 100-year-old brand, which will be celebrating next calendar year. Just iconic brands attract a super-loyal following, and we expect that to continue. In fact, by resurrecting Remington, we've had a [brand council] that we've nominated to really dig into some of the users that were disenchanted over the last number of years because they couldn't get their products. So those are the areas we're going into first. And so we're innovating in Core-Lokt to bring white-tail deer hunters on the eastern seaboard the products that they've always wanted. So there's a lot of differentiation between the two brands. And clearly, we're going to market great, great products to those loyalists and expect both of them to continue to drive their specific

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Hey. Thanks. Good afternoon, everybody. Just maybe a question on the revenue outlook for the back half of the year. So obviously you are maintaining your outlook and that's fantastic. I guess, when we think about volumes do you feel like the network is at all constrained in order to take on incremental volume? I mean, do you think you're running kind of below what the demand environment would be able to sort of provide you? And then in that context, how do you feel about sort of service, are there some improvements that need to be made, whether those heads coming back on or otherwise so you can kind of reach maybe full potential from a volume growth perspective in the back half?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you. Appreciate it.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, it's skewed more to conversion obviously. So it trends more toward our more higher conversion brand, so Quality, Econo Lodge, Rodeway, Comfort Inn as well. We do, what we call, more higher end conversions for that brand. But as we also stated, if you look at the performance of the extended stay segment the WoodSpring brand as well as Cambria which are all both new construction brands those did well as well on a relative basis. So I wouldn't -- yeah, to me we do look at that to see if there's any trends there. But we feel really good about both the new construction contracts that we did as well as the conversion contracts we did across the portfolio.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Absolutely. And that's actually because so much of that activity is a little baked in based on what happened in 2020. That's why we're a little more comfortable giving you a forward projection on growth in adjusted direct premiums. And it gets obviously a lot more difficult as we think about the COVID-related claims and then the impact on persistency associated with the pandemic.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
It is going a little too far. I mean, I think we're not ready yet to commit to anything next year other than we do believe that demand is relatively strong. We do believe that inflation is going to continue, and we do believe we've got to put price increases out there to cover inflation. And not just the raw materials, as I mentioned, but covering the freight, covering the raw material and also covering anticipated wage inflation as well. So that's the work we're going through right now, but we want to get as close to accurate as possible.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Excellent. Thank you.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I'd say it's up. So, just in general, on projects under about $150 million, we're up probably about $400 million to $500 million for this, even this month versus what we've seen in the prior year. So, quite a bit. Projects over $150 million -- again, we've been a lot more selective in what we're pursuing and how we're pursuing it. As Lisa mentioned, the type of work that we're pursuing over on $150 million, a lot of that is best value procurement. Almost 3/4 of it is best value procurement. And even with the new constraints we have put on ourselves, the projects over $150 million, the pipeline is very consistent with last year, if not up slightly.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
We do. We have a CRM system that we use, proprietorially built, and we do keep an eye on that. It is a very strong period in backlog. And we are not going to share any more detail on the specifics. But I speak with great confidence in the backlog.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you. Thank you, Michael.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. I think on the pricing side, we're seeing deals at least the ones that were in our prepayment but also on what we're seeing in the competition. The 3 handles has been broken quite substantially. We're seeing deals done in the 250 range with longer terms.
Going out 10 years that we're seeing IO deals out there for a very long period of time. On structure, we're basically seeing more leverage than we like to -- we believe the risk reward is on balance at that point with the leverage goal is so high. So I think that's where we're seeing most on the structure is the high leverage. No PGEs, et cetera and the terms are as I defined earlier, hopefully that answers it?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
The 2.2 million registrations are more in the U.S. than the normal proportion of our business was, right? So over, what was it? [Speech Overlap] 65% of the expectedly affected devices are in U.S., but the proportion of registrations in the U.S. is higher. That's also because we were out of the gate faster with the patient engagement program and the network of DMEs is very strong in the U.S., whereas in some of the international markets, it takes a bit longer to reach people, but we expect that to catch up soon.
Obviously, most of the reports are with DS1 because that's by far the vast majority of devices affected. So unless I misunderstand your question, it's logical that the vast majority of these registrations are DS1 users. On the foam, I value to state that when the product DS1 was released, it was tested against all the standards in place, including VOC standards at that time, right? And the product, of course, met all those standards. Otherwise, it would never have been released.
The foam has been used for over ten years, and we never had any issue with it. Whether the manufacturer itself had its own approvals, I am over asked here at this moment. But I repeat that we have been using this foam for ten years in DreamStation 1 and prior generations and never had issues with it.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you. Good morning, everyone. We wanted to spend a little time on packing the new customer cohort. If you could share with us some of the insights from the new customers you've gained. And I think you had implemented some incremental CRM initiatives related to some of your marketing. So if you could talk a little bit about whether it's appointment reminders or prompts to try to reactivate lapsed customers? Anything you can share with us around success of some of those digital initiatives and your new customer cohorts that would be very helpful? Thank you.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning, Ken.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi, Andrew.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good afternoon, Casey.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
NO. Not yet. No.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So, I think, as Wade said, we're kind of early in kind of our relaunch of that. Pleased, again, very early on what we're seeing from the projects we've done. So, nothing to indicate, you know, we shouldn't see the strong high single-digit lifts in our kind of lower-tier projects that will do up to well above double-digit lifts for stores we relocate.
We have no indication that we won't see that. We're well into our planning for the 60 projects we intend to do next year. We've identified most of those already, and the pro forma expectations we have with those are in line with those types of lifts.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I could. Daniel is staring at me very intensely right now.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. So yes, we'll see how that goes. I mean our plans are to feed Kemerton from Talend. And then as we either bring on other capacity or do an acquisition, we would use Wodgina for that.
and our strategy about selling spodumene hasn't changed.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. I think we hit the new record both in dollar as in number of deals, 55 deals. This quarter was very strong with 21 deals that we don't necessarily recognize all of those deals. Specifically in Q4, we had hands full of customers, new customers for us, some of them [Phonetic] that we were more concerned. So we can upfront the payment before we release the technology, but still [Phonetic] we did not recognize every one of them, so it's the wrong math to do to take the licensing revenues and divide it by 21, it's a bit of a different number.
And with that said, some of these guys that as soon as they pay us, we will deliver and be able to recognize in -- hopefully, in Q1, maybe some will take longer. We'll see, but an excellent pipeline to start the year, licensing for us right now within the Q1 is strong. So I hope I managed to give you the color here you asked about.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
We did mention price as one of the levers that we're looking at as we try to optimize the back half of the year, if there may be some situations where that could work. But we have -- so we are predicting very -- 8% to 13% growth. There is still a tremendous amount of robots to move, and it's a complex year. But that's one of the reasons why we wanted to mention price as being on the table as something we would consider.

    Prediction (one of UP, DOWN, SAME): SAME